Praxis Precision Medicines (Nasdaq: PRAX) reported positive Phase I/II data from the EMBRAVE Part A trial of elsunersen in pediatric SCN2A developmental epileptic encephalopathy (SCN2A-DEE). The antisense oligonucleotide produced a 77% placebo-adjusted seizure reduction — results that could support development of the first genotype-directed therapy for SCN2A-DEE with potential disease-modifying effects if the signal holds in the registrational study.
Trial specifics
The EMBRAVE Part A trial is a randomized, placebo-controlled Phase I/II study enrolling nine pediatric patients aged 2–12 years with early-seizure onset SCN2A-DEE, randomized 3:1 to elsunersen or sham procedure over 24 weeks, followed by an open-label extension.
Elsunersen produced a 77% placebo-adjusted reduction in monthly seizure frequency (p=0.015; 95% CI [33, 92]) — the primary efficacy signal reported. Seventy-one percent of treated patients achieved greater than 50% seizure reduction by period six, and 57% experienced at least one 28-day seizure-free period. Benefit persisted in the open-label extension for up to one year. All treated patients showed improvement in at least one non-seizure domain — sleep, motor function, muscle tone, attention, or neuropsychomotor development — compared with no improvements in the placebo group.
No drug-related serious adverse events, discontinuations, or neuroinflammation signals were observed at doses up to 8 mg. Treatment-emergent adverse events were predominantly mild to moderate.
Elsunersen and the competitive context
Elsunersen is an antisense oligonucleotide designed to reduce SCN2A mRNA levels, thereby lowering expression of the Nav1.2 sodium channel — the protein encoded by gain-of-function SCN2A mutations that drive hyperexcitability in early-onset SCN2A-DEE. The approach is mechanistically distinct from the sodium channel blockers currently used in clinical practice: rather than modulating channel gating, it reduces channel abundance at the transcript level. Praxis is carrying out development of elsunersen under a 2019 collaboration with Ionis Pharmaceuticals, with the molecule discovered and designed on Ionis's antisense platform. Elsunersen has received Orphan Drug and Rare Pediatric Disease designations from the FDA, as well as Orphan Drug and PRIME designations from the European Medicines Agency.
The competitive context for elsunersen is unusual. SCN2A-DEE carries no disease-specific approved therapy; clinicians manage the condition with repurposed sodium channel blockers — oxcarbazepine, carbamazepine, lacosamide, phenytoin — selected empirically based on the gain-of-function biology of the sodium channel. These agents reduce seizure frequency through symptomatic modulation of Nav channel kinetics but have not demonstrated neurodevelopmental benefit or disease modification in this population. The 77% placebo-adjusted seizure reduction and the across-the-board improvement in developmental domains observed with elsunersen in EMBRAVE Part A have no direct comparator in existing approved therapy for this indication.
The nine-patient cohort in EMBRAVE Part A is a material limitation. Statistical significance at p=0.015 in a 3:1 randomized design with seven active and two placebo patients warrants cautious interpretation; the confidence interval [33, 92] reflects the uncertainty inherent in this sample size. The magnitude of the point estimate is notable, but replication in the ongoing pivotal EMBRAVE3 study will be necessary before clinical or regulatory conclusions can be drawn. Praxis said the pivotal EMBRAVE3 study is underway.
Spot something wrong? Report an issue with this article